Catching Catalyst Pharma by surprise, FDA approves Jacobus LEMS drug for pediatric patients — based on adult data
When Catalyst Pharmaceuticals’ drug for Lambert-Eaton myasthenic syndrome (LEMS) — a rare, autoimmune disorder that affects the connection between nerves and muscles — was approved last …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.